CEO Update | 5 December 2022

A frustrating week last week as the R&D tax credits changes for SMEs proposed in the Autumn Statement were voted through the House of Commons last Thursday. This legally changes the tax rate from next April and there is no further possibility to table Commons amendments to this bill. I am well aware of the strength of feeling amongst members on this issue and the immediate impact it will have on investment decisions for 2023. However, working closely with South Cambridgeshire MP Anthony Browne, we have secured a life sciences roundtable with the Treasury Minister before Christmas to discuss how the R&D tax relief scheme can best support innovative life science companies driving UK economic growth.

Expanding MicrofluidX through Future Leaders Fellowships

Meet Cesare M. Cejas, co-founder and Vice-President - Microfluidics for MicrofluidX. Together with his co-founder, he set up a start-up in London to leverage microfluidics-based applications for cell and gene therapy applications, particularly autologous cell therapy. Read this Q&A blog about his experience of Future Leaders Fellowships (FLF) Round 5, which is a personal award offered by UKRI to support fellows to develop as impactful and influential research or innovation leaders.

bioProcessUK: Where next for sustainable biotechnologies?

Sustainability affects us all. It’s not just centred on one country or one industry, it is a collective societal goal that we should all be working towards so that we, and our flora and fauna neighbours can safely co-exist on Earth well into the future.

Lean Life Science and Cancer Research UK Launch the Oncology Development Programme (ODP2) to Accelerate Development of High Impact Novel Cancer Innovations

Targeted programme to identify and accelerate novel oncology innovations into commercially attractive assets; supported by unique insights from a collaboration of leading pharma, CROs, and subject matter experts in residence from across the global oncology R&D ecosystem.

CPI opens world-leading Medicines Manufacturing Innovation Centre in Scotland to raise the bar in pharma manufacturing

The Medicines Manufacturing Innovation Centre – a unique collaboration led by technology innovation catalyst CPI alongside 24 partner organisations from pharma, government, business, and academia – opens in Glasgow, Scotland; The Centre’s ‘Grand Challenge’ business model follows the UK Life Sciences Strategy roadmap to accelerate innovation and is driving sustainable manufacturing processes to reduce the industry’s carbon footprint.

PIR International's 2022 EU/UK Biotech Board & Executive Remuneration Study

PIR International's 2022 EU/UK Biotech Board & Executive Remuneration Study is now available.

Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform

Funding from the Bill & Melinda Gates Foundation will build on preclinical data showing the potential of nanoparticle-formulated doggybone DNA to deliver strong antibody titres and strong T cell responses.

Brainomix announces new partnership with Pixyl to expand its offering with multiple sclerosis solution

Brainomix to distribute Pixyl.Neuro.MS Software as a Service (SaaS) solution exclusively in the UK and Ireland, the Nordics and key markets across Eastern Europe. The emergence of disease-modifying drugs now offers more personalized treatment of multiple sclerosis, a neurological disorder that affects more than 2.3 million people worldwide. This has elevated the role of MRI in supporting both the diagnosis and ongoing disease monitoring and treatment response, opening the door for AI-powered solutions such as Pixyl’s Neuro.MS software to improve diagnosis and speed up treatment.

BIA Chairman appointed UK Government’s Life Sciences Investment Envoy

Dr Dan Mahony, Chair of the UK BioIndustry Association (BIA), has been appointed Life Sciences Investment Envoy by the Secretary of State for Business, Energy and Industrial Strategy. The Envoy will champion the UK life sciences sector to national and international investors to help increase investment in scaling life science companies.

Arecor to commence second clinical trial with AT278 ultra-concentrated ultra-rapid acting insulin candidate for Type 2 diabetes

Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces the BASG (Bundesamt für Sicherheit im Gesundheitswesen) clearance of the Group’s Clinical Trial Application (CTA) for AT278, an ultra-rapid acting, ultra-concentrated (500 U/mL) insulin candidate, in Type 2 diabetic patients, the primary target population.